224 related articles for article (PubMed ID: 16376058)
1. Effect of the [CCTG]n repeat expansion on ZNF9 expression in myotonic dystrophy type II (DM2).
Botta A; Caldarola S; Vallo L; Bonifazi E; Fruci D; Gullotta F; Massa R; Novelli G; Loreni F
Biochim Biophys Acta; 2006 Mar; 1762(3):329-34. PubMed ID: 16376058
[TBL] [Abstract][Full Text] [Related]
2. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9.
Liquori CL; Ricker K; Moseley ML; Jacobsen JF; Kress W; Naylor SL; Day JW; Ranum LP
Science; 2001 Aug; 293(5531):864-7. PubMed ID: 11486088
[TBL] [Abstract][Full Text] [Related]
3. Myotonic dystrophy: emerging mechanisms for DM1 and DM2.
Cho DH; Tapscott SJ
Biochim Biophys Acta; 2007 Feb; 1772(2):195-204. PubMed ID: 16876389
[TBL] [Abstract][Full Text] [Related]
4. Mutant (CCTG)n expansion causes abnormal expression of zinc finger protein 9 (ZNF9) in myotonic dystrophy type 2.
Raheem O; Olufemi SE; Bachinski LL; Vihola A; Sirito M; Holmlund-Hampf J; Haapasalo H; Li YP; Udd B; Krahe R
Am J Pathol; 2010 Dec; 177(6):3025-36. PubMed ID: 20971734
[TBL] [Abstract][Full Text] [Related]
5. CCUG repeats reduce the rate of global protein synthesis in myotonic dystrophy type 2.
Schneider-Gold C; Timchenko LT
Rev Neurosci; 2010; 21(1):19-28. PubMed ID: 20458885
[TBL] [Abstract][Full Text] [Related]
6. Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect.
Bachinski LL; Udd B; Meola G; Sansone V; Bassez G; Eymard B; Thornton CA; Moxley RT; Harper PS; Rogers MT; Jurkat-Rott K; Lehmann-Horn F; Wieser T; Gamez J; Navarro C; Bottani A; Kohler A; Shriver MD; Sallinen R; Wessman M; Zhang S; Wright FA; Krahe R
Am J Hum Genet; 2003 Oct; 73(4):835-48. PubMed ID: 12970845
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a single nucleotide polymorphism in the ZNF9 gene and analysis of association with myotonic dystrophy type II (DM2) in the Italian population.
Vallo L; Bonifazi E; Borgiani P; Novelli G; Botta A
Mol Cell Probes; 2005 Feb; 19(1):71-4. PubMed ID: 15652222
[TBL] [Abstract][Full Text] [Related]
8. DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression.
Margolis JM; Schoser BG; Moseley ML; Day JW; Ranum LP
Hum Mol Genet; 2006 Jun; 15(11):1808-15. PubMed ID: 16624843
[TBL] [Abstract][Full Text] [Related]
9. [Molecular pathways to myotonic dystrophy].
Ishiura S
Nihon Rinsho; 2005 Mar; 63(3):515-21. PubMed ID: 15773354
[TBL] [Abstract][Full Text] [Related]
10. ZNF9 activation of IRES-mediated translation of the human ODC mRNA is decreased in myotonic dystrophy type 2.
Sammons MA; Antons AK; Bendjennat M; Udd B; Krahe R; Link AJ
PLoS One; 2010 Feb; 5(2):e9301. PubMed ID: 20174632
[TBL] [Abstract][Full Text] [Related]
11. Expanded [CCTG]n repetitions are not associated with abnormal methylation at the CNBP locus in myotonic dystrophy type 2 (DM2) patients.
Santoro M; Fontana L; Maiorca F; Centofanti F; Massa R; Silvestri G; Novelli G; Botta A
Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):917-924. PubMed ID: 29291944
[TBL] [Abstract][Full Text] [Related]
12. Biomolecular identification of (CCTG)n mutation in myotonic dystrophy type 2 (DM2) by FISH on muscle biopsy.
Cardani R; Mancinelli E; Sansone V; Rotondo G; Meola G
Eur J Histochem; 2004; 48(4):437-42. PubMed ID: 15718211
[TBL] [Abstract][Full Text] [Related]
13. Myotonic dystrophy type 2: human founder haplotype and evolutionary conservation of the repeat tract.
Liquori CL; Ikeda Y; Weatherspoon M; Ricker K; Schoser BG; Dalton JC; Day JW; Ranum LP
Am J Hum Genet; 2003 Oct; 73(4):849-62. PubMed ID: 14505273
[TBL] [Abstract][Full Text] [Related]
14. A long PCR-based molecular protocol for detecting normal and expanded ZNF9 alleles in myotonic dystrophy type 2.
Bonifazi E; Vallo L; Giardina E; Botta A; Novelli G
Diagn Mol Pathol; 2004 Sep; 13(3):164-6. PubMed ID: 15322428
[TBL] [Abstract][Full Text] [Related]
15. New methods for molecular diagnosis and demonstration of the (CCTG)n mutation in myotonic dystrophy type 2 (DM2).
Sallinen R; Vihola A; Bachinski LL; Huoponen K; Haapasalo H; Hackman P; Zhang S; Sirito M; Kalimo H; Meola G; Horelli-Kuitunen N; Wessman M; Krahe R; Udd B
Neuromuscul Disord; 2004 Apr; 14(4):274-83. PubMed ID: 15019706
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Methods to Monitor RNA Biomarkers in Myotonic Dystrophy.
Wojciechowska M; Sobczak K; Kozlowski P; Sedehizadeh S; Wojtkowiak-Szlachcic A; Czubak K; Markus R; Lusakowska A; Kaminska A; Brook JD
Sci Rep; 2018 Apr; 8(1):5885. PubMed ID: 29651162
[TBL] [Abstract][Full Text] [Related]
17. Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms.
Meola G; Cardani R
Biochim Biophys Acta; 2015 Apr; 1852(4):594-606. PubMed ID: 24882752
[TBL] [Abstract][Full Text] [Related]
18. Absence of a differentiation defect in muscle satellite cells from DM2 patients.
Pelletier R; Hamel F; Beaulieu D; Patry L; Haineault C; Tarnopolsky M; Schoser B; Puymirat J
Neurobiol Dis; 2009 Oct; 36(1):181-90. PubMed ID: 19632331
[TBL] [Abstract][Full Text] [Related]
19. Haploinsuffciency for Znf9 in Znf9+/- mice is associated with multiorgan abnormalities resembling myotonic dystrophy.
Chen W; Wang Y; Abe Y; Cheney L; Udd B; Li YP
J Mol Biol; 2007 Apr; 368(1):8-17. PubMed ID: 17335846
[TBL] [Abstract][Full Text] [Related]
20. [Myotonic dystrophy].
Nanba E
Nihon Rinsho; 2005 Mar; 63(3):429-33. PubMed ID: 15773341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
